Bouzakri Karim, Zierath Juleen R
Department of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, S-171 77 Stockholm, Sweden.
J Biol Chem. 2007 Mar 16;282(11):7783-9. doi: 10.1074/jbc.M608602200. Epub 2007 Jan 16.
Tumor necrosis factor-alpha (TNF-alpha) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-alpha-induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH2-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF-alpha-induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF-alpha-induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF-alpha. Depletion of MAP4K4 also prevented TNF-alpha-induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF-alpha-treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF-alpha-induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake.
肿瘤坏死因子-α(TNF-α)通过损害参与葡萄糖转运蛋白4(GLUT4)转位的胰岛素信号事件来诱导骨骼肌胰岛素抵抗。我们测试了促分裂原活化蛋白激酶激酶激酶激酶4型(MAP4K4)是否导致TNF-α诱导的对细胞外信号调节激酶1/2(ERK-1/2)、c-Jun氨基末端激酶(JNK)以及胰岛素受体底物-1(IRS-1)在调控葡萄糖代谢的胰岛素信号通路中的负调节。使用小干扰RNA(siRNA)将原代人骨骼肌细胞中MAP4K4蛋白的表达抑制85%,我们提供证据表明TNF-α诱导的对葡萄糖摄取的胰岛素抵抗被完全阻止。MAP4K4沉默通过防止过度的JNK和ERK-1/2磷酸化以及IRS-1丝氨酸磷酸化来抑制TNF-α诱导的负信号输入。这些结果突出了MAPK4K4/JNK/ERK/IRS模块在响应TNF-α时对胰岛素信号向葡萄糖转运的负调节作用。MAP4K4的缺失还阻止了TNF-α诱导的对Akt和Akt底物160(AS160)的胰岛素抵抗,这提供了证据表明恢复了用于葡萄糖代谢的适当胰岛素信号输入。MAP4K4下游的信号蛋白MAP2K1和MAP2K4的沉默在TNF-α处理的细胞中重现了MAP4K4 siRNA的作用。因此,抑制MAP4K4的策略可能在预防TNF-α诱导的导致人类骨骼肌葡萄糖代谢胰岛素抵抗的抑制信号方面有效。此外,在胰岛素抵抗的II型糖尿病患者的肌管中,针对MAP4K4、MAP2K4或MAP2K1的siRNA将胰岛素对葡萄糖摄取的作用恢复到健康受试者中观察到的水平。总体而言,我们的结果表明MAP4K4沉默可预防人类骨骼肌中的胰岛素抵抗,并恢复适当的信号输入以增强葡萄糖摄取。